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In the last decade, we have found an increased incidence of gastrointestinal (GI) malignancies among Cystic Fibrosis (CF) patients. We discuss
the case of a 30-year-old woman of mixed descent, with CF, who was referred to the emergency department for persistent abdominal pain and
constipation, complicated by blood-streaked stools. On physical examination, her abdomen was soft, nontender, and without organomegaly or
palpable masses. Rectal examination was unrevealing. The patient's initial laboratory evaluation revealed a hemoglobin level of 11.7g/dl. A CT
scan of the abdomen was unremarkable. A colonoscopy performed one day after admission showed an intraluminal mass in the proximal Sigmoid
Colon, from which biopsies were taken. Pathology reports subsequently revealed invasive Adenocarcinoma of the Colon. The patient underwent
tumor resection followed by initiation of chemotherapy. The pathophysiology underlying the increased risk of GI cancers in CF patients is
unknown. Possible explanations include genetic mutations or persistent pathologic alterations in digestive tract structures. It is our hope that this
case will bring to light the need to further delineate cancer risk among CF patients and to develop screening recommendations tailored to this
population.
© 2008 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic Fibrosis; Colon Cancer; Adenocarcinoma; Cystic Fibrosis Transmembrane Regulator (CFTR); MUC geneContents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 343
2. History and clinical features . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 343
3. Treatment and outcome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 344
4. Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 344
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3461. Introduction
As the life expectancies of Cystic Fibrosis (CF) patients have
increased, so has variability in disease manifestations. In re-
peated studies, CF patients have been shown to have a higher⁎ Corresponding author. Faculty, Department of Internal Medicine, 205 S.
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doi:10.1016/j.jcf.2008.02.006than expected rates of gastrointestinal (GI) malignancies. The
etiology of this association is not clear, and poses a challenge
for clinical medicine—defining the optimal strategy for
neoplastic screening in this vulnerable population. To illustrate
this point, we present the case of one such patient.
2. History and clinical features
The patient is a 30-year-old woman of mixed Caucasian and
African-American descent who was referred by her Cystic
Fibrosis clinic to the Emergency Department for persistent leftd by Elsevier B.V. All rights reserved.
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of similar pain which had become sharper and more intense.
The patient also noted a protuberant area in the left lower
quadrant. She denied any fevers or chills. The medical interview
revealed hematochezia consisting of bloody streaks on the out-
side of her stools.
With the exception of CF, the patient's past medical history
was only notable for chronic constipation. The patient's past
surgical history was notable for an Appendectomy, Cholecys-
tectomy, and Umbilical Hernia Repair. Her family history did
not reveal any Colon Cancer, GI polyps, or Inflammatory
Bowel Disease; but did reveal a history of nonspecific “Colitis”
in her grandmother, who also suffered from Irritable Bowel
Syndrome. The patient reported that she rarely ingested alco-
holic beverages and did not use tobacco products.
A Colonoscopy, performed one day after admission, showed
an intraluminal mass in the proximal Sigmoid Colon, which was
subsequently identified as invasive Adenocarcinoma of the Colon
(Fig. 1). A CT scan performed as part of the GI malignancy
evaluation was found to be unremarkable. The patient then
underwent an Exploratory Laparotomy. At that time, pathologic
tumor staging revealed a T3N0M1, stage IV Colon Cancer.
Medical Oncology and General Surgery were then consulted. Of
note is that a GI workup, for complaints of rectal bleeding and
persistent constipation, which included a Colonoscopy fifteen
months prior to this cancer diagnosis, did not reveal any malig-
nancies. Despite a reportedly adequate bowel preparation, the
procedure only showed three polyps; two Tubular Adenomas in
the Descending Colon and one Tubulovillous Adenoma in the
Sigmoid Colon. According to this patient's operative report; these
lesions were removed without incident and the patient was diag-
nosed with Functional Constipation.
3. Treatment and outcome
On hospital day seven, the patient underwent an Exploratory
Laparotomy, with the following findings: a 4 cm mass in the
Sigmoid Colon, as well as metastases to the right Ovary, Douglas'Fig. 1. Sigmoid Colon specimen showing moderately to poorly differentiated
Adenocarcinoma.Pouch, and the abdominal wall. This prompted a Sigmoidectomy,
Hartman's Procedure, right Oophorectomy, and an excision of a
peritoneal wall mass.
Because themass inDouglas' Pouchwas invading theRectum,
a Colostomy was created as well. The patient's post-operative
course was complicated by a pneumonia; which, based on pre-
hospital sputum-culture data, was treated with IV antibiotics
(Ceftazidime and Tobramycin). The patient was then discharged
to the care of a Medical Oncology group in her hometown
and received four courses of chemotherapy with 5-Fluorouracil,
Oxaliplatin, Leucovirin, and Avastin.
4. Discussion
Over the last thirty years, the face of CF has changed. As the
patient population has increasingly lived into adulthood, the
perception of CF as a childhood affliction has begun to change.
We are starting to realize that as this population ages; they
exhibit higher than expected rates of certain dreaded diseases
such as cancer. In 1993, Sheldon et al. conducted the first cohort
study investigating the association between CF and malignancy.
In this study, a possible association was established between CF
and Adenocarcinoma of the Pancreas and of the Terminal Ileum.
However, limited conclusions can be drawn from Sheldon's
publication, since only one case of each malignancy was re-
ported [1].
Subsequent studies of this association have yielded more
conclusive results. In 1995, Neglia et al. conducted a retro-
spective cohort study looking at the occurrence of cancer in
28,511 CF patients from 1985 through 1992. A mildly increased
incidence of digestive tract tumors was noted. In North
America, thirteen tumors were observed as compared with an
expected occurrence of only two. In Europe, eleven of thirty-
nine observed cancers originated in the digestive tract, yielding
a positive association between digestive tract tumors and CF
[2]. Additional support for this association between CF and GI
malignancies can be found in Maisonneuve's study, where a
statistically significant increase in the incidence of gastro-
intestinal malignancies was observed (23 observed versus 4.5
expected). This paper reported a greater than expected number
of digestive tract cancers, particularly in the Small Intestine,
Colon, and Biliary Tract. Interestingly, this association did not
hold true for the Stomach or Rectum [3].
Studies investigating the association between CF and gastro-
intestinal malignancies have suggested that the mean time
between diagnosis of CF and subsequent diagnosis of neoplasm
is 35 years [3]. This would suggest that the pathologic mech-
anism for GI malignancies requires a prolonged period, ex-
tending into adulthood. Thus, as we become more effective in
treating the CF patient's pulmonary and malnutrition-related
morbidities, and improving his or her life expectancy, other
maladies may arise.
In discussing morbidity associated with CF, a patient's geno-
type has strong prognostic significance. Consequently, a pa-
tient's genotype would be expected to affect cancer risk. To
support this point, Neglia's study found that 67% of patients
(fourteen in total) were homozygous for theΔF508 mutation [2].
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tract cancer was highest for patients homozygous for the ΔF508
mutation, intermediate for patients heterozygous for the muta-
tion, and lowest for patients carrying other mutations. Although
most research to date suggests a strong association with the
ΔF508 mutation state, it is conceivable that separate and distinct
mutations or gene linkages, not routinely tested for, may be
modifying this patient population's GI cancer risk.
In investigating novel gene linkages; an association with the
MUC3, MUC11, and MUC12 genes has been postulated as a
contributing factor in the development of GI malignancies. The
MUC gene family is responsible for the production of mucin
glycoproteins which are secreted by epithelial cells and re-
sponsible for cell surface protection, protein adhesion to cell
surfaces, and enzymatic signaling. It is postulated that “mucins
may play a role in CF because patients with the same Cystic
Fibrosis Transmembrane Regulator (CFTR) gene mutation can
differ with respect to mucus obstruction.” [3] Based on linkage
analyses, it is known that the CFTR gene is found in the
chromosome band next to the MUC3, MUC11, and MUC12
genes. Furthermore, MUC11 and MUC12 expression is altered
in tissues typically affected by CF manifestations. Therefore,
decreased expression of MUC3, MUC11, and MUC12 might
explain the increased numbers of small bowel and colon can-
cers, as well as those of the Esophagus and oral mucosa, which
have been observed in CF patients [3].
In a fashion akin to the survival advantage conferred on
individuals with the sickle-cell trait, a survival advantage has
been conjectured to be associated with the CF carrier state [4].
Indeed, the CF carrier state is felt to confer a degree of pro-
tection from dehydration due to infectious diarrhea, particularly
from Cholera outbreaks [5]. This would explain the high fre-
quency of heterozygous CF carriers in the population [4]. Also
akin to the natural history of the sickle-cell mutation, the ho-
mozygous or heterozygous state of two CFTR mutations con-
fers morbidity; including an increased risk of constipation,
pancreatic insufficiency, and GI malignancy.
In addition to their pulmonary maladies, CF is often thought
to be a disease of malnutrition. Indeed, the literature has started to
address how this predisposition to malnutrition could affect
cancer risk. Neglia's work revealed that Failure-to-Thrive, as a
presenting sign of CF, has strong prognostic significance for later
gastrointestinal malignancy [2]. In light of the genetic predis-
positions discussed above, this symptomatic association may
suggest that a combination of genetics and morbidity contribute
to the link between CF and GI malignancy. One explanation is
that both malnutrition and the specific mutation are indicators of
CF symptom severity and prognosis. This point is exemplified by
the fact that 58% of patients diagnosed with Failure-to-Thrive or
malnutrition are homozygous for the ΔF508 mutation [3].
One compelling clinical consideration in CF patients is that
many of the signs and symptoms of gastrointestinal malignancy
are similar to those of nonmalignant gastrointestinal disease.
However, to date, no correlation has been found between gas-
trointestinal complications such as Acute Gastrointestinal Tract
Bleeding, Cirrhosis, Distal Intestinal Obstructive Syndrome,
Fibrosing Colonopathy or Rectal Prolapse with the later de-velopment of digestive tract neoplasms [3]. In the case of our
index patient, her worsening constipation may have been a sign
of intraluminal occlusion and not merely the typical obstipation
seen in many CF patients, due to inspissated bowel contents.
However; a colonoscopic evaluation of this patient, performed
fifteen months before her cancer diagnosis, did not reveal any
evidence of malignancy.
This case presentation raises some other questions. Speci-
fically, what role did this patient's gender or race play in the
development of her gastrointestinal malignancy?
Based on the work of Neglia, gender does not make a
difference in the pattern of observed versus expected cases of
cancer. However, a patient's race might be a risk factor. In
Neglia's research, all the cancers studied occurred in Caucasian
patients [2]. According to Maisonneuve's article, most of the
CF patients studied were Caucasian (95.8%), with only a small
proportion having African-American decent (3.6%). Indeed, all
but one cancer arose in Caucasian patients [3]. Interestingly,
our index patient is of mixed Caucasian and African-American
descent. Another curious finding concerns the abdominal CT
results. It is conjectured that a paucity of retroperitoneal and
intrabdominal fat may lead to crowding of the bowel loops and
poor resolution for metastases of intrabdominal neoplasms.
Given the predisposition of CF patients to malnutrition, CT
findings may have a higher likelihood of being falsely negative
than in the general population. Our patient's false negative CT
findings may also be explained by less than adequate bowel
preparation, with oral contrast. The resolution of this scan could
have been increased by the simultaneous use of rectal contrast,
along with oral contrast.
Transplant patients provide an interesting subgroup of CF
patients regarding GI cancer risk. The risk of developing a
malignancy appears to be more pronounced after transplant
procedures, including lung transplantation. According to Mai-
sonneuve; in studying 1063 CF patients who underwent a lung
transplant, 13 cancers were reported, although only 2.05 cases
were expected to have occurred. Four of these cancers were GI-
related, including one small bowel neoplasm. In discussing this
finding, Maisonneuve believes that post-transplant immuno-
suppressive therapy plays a role in the strength of this association
[3].
One of the issues that this case raises is what is the optimal
screening strategy for patients with CF? This patient had no
family history of Colon Cancer or any other syndrome which
would have prompted early screening. Based on the finding of
three polyps on Colonoscopy, fifteen months prior to her cancer
diagnosis, she should have not been due for a repeat colo-
noscopy for three years [6]. As the prevalence of Crohn's
Disease has been found to be seventeen-fold higher in CF
patients than the general population, it is conceivable that the
neoplastic mechanism which eventually leads to GI malig-
nancies relates to progression of dysplasia through expression
of mutant genes [7]. Thus, mutation-initiated tissue dysplasia
may play a role in the pathogenesis of CF-associated GI malig-
nancies. Recognizing that dysplastic tissue may not be visible,
current recommendations for Colon Cancer screening in Inflam-
matory Bowel Disease (IBD) call for four-quadrant biopsies at
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Thus, our patient may have had tissue dysplasia which was not
found, because the search on Colonoscopy was not extensive
enough.
Likewise, the guidelines typically applied to Inflammatory
Bowel Disease do not help us to clarify when is the appropriate
time to screen CF patients nor the appropriate interval between
screening tests, once this process has been initiated. Presumably,
this patient had all visible “early adenomas” removed at her
initial Colonoscopy. If we are to apply similar guidelines to those
used in IBD, this patient should have started the screening
process 8–10 years after beginning to suffer from GI symptoms.
This would argue for initiation of the screening process while
the CF patient is still in childhood; a recommendation that is
only used for familial polyp syndromes such as FAP [9]. A
more reasonable guideline may be inferred from the work of
Maisonneuve, who found a mean interval of 35 years between
the diagnosis of CF and the diagnosis of the GI malignancy [3].
Given the issues of vitamin malabsorption, malnutrition, and
constipation which are associated with mutations of the CFTR
gene, Colonoscopywould seem to be the recommended screening
modality for CF patients, as with other populations to be screened
for colorectal neoplasms.
In conclusion, there is a growing body of literature, which
shows an association between CF and Colon Cancer. Should
this association be supported by future research, Colon Cancer
screening in CF patients should be initiated at a younger age
than in the general population. Unfortunately, no definitive
answers on the optimal age or interval for colorectal cancer
screening can be drawn from the available literature.
We have been very successful at treating the childhood
manifestations of Cystic Fibrosis. Consequently, our CF patientpopulation is aging and starting to experience diseases typically
associated with adulthood. Given the emerging predisposition
of this population to such dreaded diseases as Colon Cancer,
increasing time and energy will need to be devoted to de-
lineating the optimal screening and prevention strategy for this
group of patients. Potential associations between Cystic Fibro-
sis and neoplastic disease remain a topic of much speculation. It
is our hope that this case discussion will motivate further study
to define what the optimal cancer screening and prevention
strategy should be for this patient population.
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